Literature DB >> 2713862

Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma.

S Del Vecchio1, J C Reynolds, J A Carrasquillo, R G Blasberg, R D Neumann, M T Lotze, G J Bryant, R J Farkas, S M Larson.   

Abstract

Regional measurements of 131I-9.2.27 distribution in human melanoma tumors were obtained using quantitative autoradiography. Tumors were removed from patients 72-96 h after they had received an i.v. injection of 9.15 mCi (100 mg) of 131I-9.2.27. The autoradiographic images showed that the radioactivity reaching the tumor was heterogeneously distributed. Areas of relative high and low uptake were selected in each tumor. Regions of high activity contained from 51 to 1371 nCi/g, while areas with low uptake had radioactivity ranging from 12 to 487 nCi/g. The reliability of the autoradiographic measurements was demonstrated by the strong positive correlation with direct tissue sample counting (r = 0.994 P less than 0.001). Since comparative immunocytochemistry showed a homogeneous and diffuse staining of target antigen on viable tumor cells, variability of monoclonal antibody uptake within individual tumors was not primarily due to heterogeneity of antigen expression in these cases. However, antigen levels accounted for some of the variation from tumor to tumor. When immunoperoxidase staining was repeated on adjacent sections without the addition of 9.2.27, it confirmed the nonuniform distribution of monoclonal antibody found at autoradiography. Thus, quantitative autoradiography gives information about the distribution and the local concentration of radioactive antibody in tumors allowing calculation of the radiation dose delivered to small regions within tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713862

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Monoclonal antibody uptake in B-cell lymphomas: experimental studies in nude mouse xenografts.

Authors:  J Schmid; P Möller; G Moldenhauer; B Dörken; H Bihl; S Matzku
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

2.  Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.

Authors:  Aman P Singh; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Greg M Thurber; Dhaval K Shah
Journal:  AAPS J       Date:  2020-01-14       Impact factor: 4.009

Review 3.  Immunotherapy with monoclonal antibodies in metastatic melanoma.

Authors:  T A Steffens; D F Bajorin; A N Houghton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

4.  Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer.

Authors:  S Del Vecchio; L Mansi; A Petrillo; L Camera; M Sofia; A Marra; L Carratù; M Salvatore
Journal:  Eur J Nucl Med       Date:  1991

Review 5.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

6.  Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy.

Authors:  J F Hainfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

7.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

8.  Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.

Authors:  K Bosslet; A Steinstraesser; P Hermentin; L Kuhlmann; A Bruynck; M Magerstaedt; G Seemann; A Schwarz; H H Sedlacek
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

9.  Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.

Authors:  Katrin P Guillen; Carla Kurkjian; Roger G Harrison
Journal:  J Biomed Sci       Date:  2014-07-22       Impact factor: 8.410

Review 10.  Targeting enzymes for cancer therapy: old enzymes in new roles.

Authors:  M P Deonarain; A A Epenetos
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.